arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nuvation Bio Inc.

NUVB
$5.70 ▼ -0.40 (-6.56%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nuvation Bio Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.0M
Dividend Yield
Revenue Growth 555.6%
Op. Margin -161.1%
ROIC -10.3%
FCF / Share $-123.20
Trailing P/E
Price / Book 7.8x
FCF Yield
Debt / Equity 0.98
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.69M
↑ +555.6%
Net Income Profit after all expenses
$5.40M
— 0.0%
Operating Margin Operating profit as % of sales
-161.1%
↓ -3554.0% 0th
FCF / Share Free cash flow per share
$-123.20
↓ -944.2%
Long-Term Debt Long-term obligations
$242.62M
↑ +412.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
13
Financial Health
45
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters